A Phase 2 interventional study of branebrutinib and abatacept in Autoimmune Disorder, Rheumatoid Arthritis and Systemic Lupus Erythematosus, sponsored by Bristol-Myers Squibb. Completed at 81 sites in 10 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-01-16.
Sponsored by Bristol-Myers Squibb · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 341 studies in Autoimmune Diseases with a site in United States — 91 open to participants now, 117 under way, 19 of them phase 3. Autoimmune Diseases · United States.
Among the 341 studies in Autoimmune Diseases with a site in United States, this one is the 71st largest by enrollment of the 243 interventional ones that give a count, is one of 17 that started in 2020, is one of 75 in phase 2, and was the 206th registered.
803 studies on the registry are indexed under Autoimmune Diseases; 272 are open to participants now.
Browse Autoimmune Diseases studies →91 of the 341 studies in Autoimmune Diseases with a site in United States are open now. Recruiting first, the newest first:
Jade Biosciences, Inc. · Sites in United States
Ages 18+
National Human Genome Research Institute (NHGRI) · Sites in United States, Peru
Ages 18–115
PTC Therapeutics · Sites in United States, Georgia, Mauritius and 1 more country
Ages 18–70
iCell Gene Therapeutics · Sites in United States
Ages 16–70
University of Washington · Sites in United States, Netherlands
Ages 18–69
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
341 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 82 · Phase 2 100 · Phase 3 47 · Phase 4 12
First in 1991; this study’s year is marked. 17 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 119 is above the median of 40 across 542 interventional studies indexed under Autoimmune Diseases.
Median enrollment 53 across the 243 interventional studies, 420 across the 95 observational. Of the 209 that completed or were terminated, 79 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
147 of 341 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Bristol-Myers Squibb has 8 studies filed under Autoimmune Diseases — fewer than ten, so there is no comparison to draw.
34 of the studies in Autoimmune Diseases with a site in United States that are under way reach primary completion within a year, 6 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07059000Phase 3Kedrion S.p.A.A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP) | 2026-12 |
| NCT05672576Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Efficacy and Safety of Cenerimod in Subjects Suffering From Systemic Lupus Erythematosus | 2026-12-31 |
| NCT05925803Phase 3AstraZenecaDetermine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY) | 2027-01-06 |
| NCT05648500Phase 3Viatris Innovation GmbHA Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | 2027-03-31 |
| NCT06056297Phase 3X4 PharmaceuticalsA Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | 2027-09 |
Add all 34 to your calendar (.ics) → With an account.
Among the 341 studies in Autoimmune Diseases with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and effectiveness of treatment with branebrutinib treatment in participants with active systemic Lupus Erythematosus (SLE) or Primary Sjögren's Syndrome (pSS), or branebrutinib treatment followed by open-label abatacept treatment in study participants with active Rheumatoid Arthritis (RA).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Sub-study for Systemic Lupus Erythematosus (SLE)
Sub-study for primary Sjögren's Syndrome (pSS)
Sub-study for active Rheumatoid Arthritis (RA)
Women and men must agree to follow instructions for methods of .
Exclusion Criteria:
Sub-study for SLE
Sub-study for pSS
Sub-study for RA
For all sub-studies:
Other protocol defined inclusion/exclusion criteria could apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: branebrutinib
Drug: branebrutinib placebo
Drug: branebrutinib
Drug: branebrutinib placebo
Drug: branebrutinib · Drug: abatacept
Drug: abatacept · Drug: branebrutinib placebo
Specified dose on specified days
Specified dose on specified days
Specified dose on specified days
The Percent of Participants With mCLASI Response at Week 24 and Corticosteroid (CS) < 10 mg/Day at Week 20 and Week 24 - SLE
mCLASI response is defined as a decrease of ≥ 50% from baseline mCLASI activity score, in participants with a baseline mCLASI activity score ≥ 10, at Week 24. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. To be considered as meeting the second criterion, the CS (prednisone or equivalent) dose had to remain stable and ≤ 10 mg from Week 16 until Week 24. The modified CLASI (mCLASI) is defined as the activity portions of CLASI that describe skin erythema and scale/hypertrophy and inflammation of the scalp. The percentage of patients who entered the study with a positive mCLASI activity score (≥ 10) and who achieved a ≥ 50% decrease from baseline at Week 24 is considered to likely represent a clinically meaningful improvement. The scores are calculated by simple addition based on the extent of the symptoms. mCLASI: Modified Cutaneous Lupus Erythematosus Disease Area and Severity Index
Time frame: Week 24
The Percent of Participants With Composite Response at Week 24 - pSS
Composite response is defined as the percent of participants with at least 3 of the following at Week 24: * Decrease of ≥ 1 point or 15% from baseline in the ESSPRI Total Score * Decrease of ≥ 3 points from baseline in ESSDAI score * Decrease of ≥ 25% from baseline in ocular staining score, or if normal score at baseline no change to abnormal * Increase of ≥ 25% from baseline in stimulated salivary flow * Improvement in one or more serological markers (rheumatoid factor (RF), immunoglobulin G protein (IgG), complement C3 or C4, cryoglobulin).
Time frame: Week 24
Percent of Participants With ACR50 Response at Week 12 Compared to Baseline - RA
ACR50 response is defined as both improvement of 50% in the number of tender and swollen joints and a 50% improvement in 3 of the following 5 criteria: * Subject global assessment (SGA) * Physician global assessment (PGA) * Functional ability measure * Pain visual analog scale (VAS) * Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.
Time frame: Week 12
Change From Baseline in SLEDAI-2K Score at Week 24 - SLE
The SLEDAI-2K is a global index providing a total score of overall disease activity ranging from 0 to 105, with higher scores representing more active disease. The SLEDAI index includes 24 items divided into 9 organ systems: neurological, musculoskeletal, renal, mucocutaneous, general, heart, respiratory, vascular, and hematological. Each item is scored based on the severity of the symptom or finding, with higher scores indicating more severe disease activity. The weighted scores for each item range from 0 to 8. To calculate the SLEDAI-2K score, the scores for each of the 24 items are added together. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.
Time frame: Week 24
Percent of Participants With BICLA Response at Week 24 - SLE
BILAG-based composite lupus assessment (BICLA) response is defined as: 1. At least one gradation of improvement in baseline BILAG scores in all body systems with moderate or severe disease activity at entry 2. No new BILAG A or more than one new BILAG B scores 3. No worsening of total SLEDAI score from baseline 4. No significant deterioration (\< 10%) in PGA and 5. No treatment failure (initiation of nonprotocol treatment). BILAG scores: A (severe disease), B (moderate), C (mild), or D (no activity). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.
Time frame: Week 24
Change From Baseline in DAS28-CRP at Week 12 - RA
The Disease Activity Score-28-C-Reactive Protein (DAS28CRP) is a composite outcome assessment that measures: 1) How many joints in the hands, wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28, 2) CRP in the blood to measure the degree of inflammation, and 3) SGA of disease activity. DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-CRP score, which correlates with the extent of disease activity: \< 2.6: Disease remission 2.6 - 3.2: Low disease activity 3.2 - 5.1: Moderate disease activity \> 5.1: High disease activity A negative change from baseline in DAS28-CRP indicates an improvement. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.
Time frame: Week 12
Change From Baseline in DAS28-ESR at Week 12 - RA
The Disease Activity Score Erythrocyte Sedimentation Rate - DAS28ESR is a composite outcome assessment that measures: 1. How many joints in the hands, wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28 2. ESR in the blood to measure the degree of inflammation 3. SGA of disease activity DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-ESR score, which correlates with the extent of disease activity: \< 2.6: Disease remission 2.6 - 3.2: Low disease activity 3.2 - 5.1: Moderate disease activity \> 5.1: High disease activity A negative change from baseline in DAS28-ESR indicates an improvement. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.
Time frame: Week 12
Change From Baseline in SDAI at Week 12- RA
The Simplified Disease Activity Index (SDAI) is the sum of the tender joint score (range 0 to 28), the swollen joint score (range 0 to 28), the subject global assessment (SGA) of disease activity (range 0 to 10 in increments of 0.5), the PGA of disease activity (range 0 to 10 in increments of 0.5), and C-reactive protein (CRP) test result. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. A SDAI score ranges from 0 (disease remission) to 86 (high disease activity).
Time frame: Week 12
Change From Baseline in CDAI at Week 12 - RA
The Clinical Disease Activity Index (CDAI) is the sum of the tender joint score (range 0 to 28), the swollen joint score (range 0 to 28), the SGA of disease activity (range 0 to 10 in increments of 0.5), and the PGA of disease activity (range 0 to 10 in increments of 0.5). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. A CDAI score ranges from 0 to 76. The interpretation of CDAI is as follows: 0.0 - 2.8: Disease remission 2.9 - 10.0: Low disease activity (LDA) 10.1 - 22.0: Moderate disease activity 22.1 - 76.0: High disease activity
Time frame: Week 12
Percent of Participants With ACR20 Response Compared to Baseline at Week 12 - RA
ACR20 defined as both improvement of 20% in the number of tender and swollen joints and a 20% improvement in 3 of the following 5 criteria: * Subject global assessment (SGA) * Physician global assessment (PGA) * Functional ability measure * Pain visual analog scale (VAS) * Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.
Time frame: Week 12
Percent of Participants With ACR70 Response Compared to Baseline at Week 12 - RA
ACR70 is defined as both improvement of 70% in the number of tender and swollen joints and a 70% improvement in 3 of the following 5 criteria: * Subject global assessment (SGA) * Physician global assessment (PGA) * Functional ability measure * Pain visual analog scale (VAS) * Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.
Time frame: Week 12
| Milestone | SLE- Placebo | SLE- Branebrutinib | pSS- Placebo | pSS- Branebrutinib | RA- Placebo | RA- Branebrutinib |
|---|---|---|---|---|---|---|
| Started | 5 | 15 | 4 | 10 | 21 | 64 |
| Double blind period | 5 | 15 | 4 | 10 | 21 | 64 |
| Open label period | 0 | 0 | 0 | 0 | 20 | 61 |
| Completed | 3 | 11 | 4 | 9 | 20 | 58 |
| Not completed | 2 | 4 | 0 | 1 | 1 | 6 |
| Withdrew: Lack of efficacy | 0 | 1 | 0 | 0 | 1 | 1 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 | 0 | 2 |
| Withdrew: Study terminated by sponsor | 1 | 2 | 0 | 1 | 0 | 0 |
| Withdrew: Other reasons | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 1 |
mCLASI response is defined as a decrease of ≥ 50% from baseline mCLASI activity score, in participants with a baseline mCLASI activity score ≥ 10, at Week 24. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. To be considered as meeting the second criterion, the CS (prednisone or equivalent) dose had to remain stable and ≤ 10 mg from Week 16 until Week 24. The modified CLASI (mCLASI) is defined as the activity portions of CLASI that describe skin erythema and scale/hypertrophy and inflammation of the scalp. The percentage of patients who entered the study with a positive mCLASI activity score (≥ 10) and who achieved a ≥ 50% decrease from baseline at Week 24 is considered to likely represent a clinically meaningful improvement. The scores are calculated by simple addition based on the extent of the symptoms. mCLASI: Modified Cutaneous Lupus Erythematosus Disease Area and Severity Index
| Percentage of participants | SLE- Placebo | SLE- Branebrutinib |
|---|---|---|
| The Percent of Participants With mCLASI Response at Week 24 and Corticosteroid (CS) < 10 mg/Day at Week 20 and Week 24 - SLE | 60.0 (17.1 to 100) | 33.3 (9.5 to 57.2) |
The SLEDAI-2K is a global index providing a total score of overall disease activity ranging from 0 to 105, with higher scores representing more active disease. The SLEDAI index includes 24 items divided into 9 organ systems: neurological, musculoskeletal, renal, mucocutaneous, general, heart, respiratory, vascular, and hematological. Each item is scored based on the severity of the symptom or finding, with higher scores indicating more severe disease activity. The weighted scores for each item range from 0 to 8. To calculate the SLEDAI-2K score, the scores for each of the 24 items are added together. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.
| Change in "score on a scale" | SLE- Placebo | SLE- Branebrutinib |
|---|---|---|
| Change From Baseline in SLEDAI-2K Score at Week 24 - SLE | -7.0 ± 5.29 | -7.0 ± 6.54 |
BILAG-based composite lupus assessment (BICLA) response is defined as: 1. At least one gradation of improvement in baseline BILAG scores in all body systems with moderate or severe disease activity at entry 2. No new BILAG A or more than one new BILAG B scores 3. No worsening of total SLEDAI score from baseline 4. No significant deterioration (\< 10%) in PGA and 5. No treatment failure (initiation of nonprotocol treatment). BILAG scores: A (severe disease), B (moderate), C (mild), or D (no activity). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.
| Percent of participants | SLE- Placebo | SLE- Branebrutinib |
|---|---|---|
| Percent of Participants With BICLA Response at Week 24 - SLE | 20.0 (0.5 to 71.6) | 33.3 (11.8 to 61.6) |
Composite response is defined as the percent of participants with at least 3 of the following at Week 24: * Decrease of ≥ 1 point or 15% from baseline in the ESSPRI Total Score * Decrease of ≥ 3 points from baseline in ESSDAI score * Decrease of ≥ 25% from baseline in ocular staining score, or if normal score at baseline no change to abnormal * Increase of ≥ 25% from baseline in stimulated salivary flow * Improvement in one or more serological markers (rheumatoid factor (RF), immunoglobulin G protein (IgG), complement C3 or C4, cryoglobulin).
| Percent of Participants | pSS- Placebo | pSS- Branebrutinib |
|---|---|---|
| The Percent of Participants With Composite Response at Week 24 - pSS | 25 (0.0 to 67.4) | 10 (0.0 to 28.6) |
ACR50 response is defined as both improvement of 50% in the number of tender and swollen joints and a 50% improvement in 3 of the following 5 criteria: * Subject global assessment (SGA) * Physician global assessment (PGA) * Functional ability measure * Pain visual analog scale (VAS) * Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.
| Percent of Participants | RA- Placebo | RA- Branebrutinib |
|---|---|---|
| Percent of Participants With ACR50 Response at Week 12 Compared to Baseline - RA | 33.3 (13.2 to 53.5) | 18.8 (9.2 to 28.3) |
The Disease Activity Score-28-C-Reactive Protein (DAS28CRP) is a composite outcome assessment that measures: 1) How many joints in the hands, wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28, 2) CRP in the blood to measure the degree of inflammation, and 3) SGA of disease activity. DAS28-CRP scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-CRP score, which correlates with the extent of disease activity: \< 2.6: Disease remission 2.6 - 3.2: Low disease activity 3.2 - 5.1: Moderate disease activity \> 5.1: High disease activity A negative change from baseline in DAS28-CRP indicates an improvement. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.
| Score on a scale | RA- Placebo | RA- Branebrutinib |
|---|---|---|
| Change From Baseline in DAS28-CRP at Week 12 - RA | -1.615 ± 1.19545 | -1.542 ± 1.0790 |
The Disease Activity Score Erythrocyte Sedimentation Rate - DAS28ESR is a composite outcome assessment that measures: 1. How many joints in the hands, wrists, elbows, shoulders, and knees are swollen and/or tender over a total of 28 2. ESR in the blood to measure the degree of inflammation 3. SGA of disease activity DAS28-ESR scores range from 1.0 to 9.4, where lower scores indicate less disease activity. The results are combined to produce the DAS28-ESR score, which correlates with the extent of disease activity: \< 2.6: Disease remission 2.6 - 3.2: Low disease activity 3.2 - 5.1: Moderate disease activity \> 5.1: High disease activity A negative change from baseline in DAS28-ESR indicates an improvement. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.
| Score on a scale | RA- Placebo | RA- Branebrutinib |
|---|---|---|
| Change From Baseline in DAS28-ESR at Week 12 - RA | -1.758 ± 1.1932 | -1.670 ± 1.1487 |
The Simplified Disease Activity Index (SDAI) is the sum of the tender joint score (range 0 to 28), the swollen joint score (range 0 to 28), the subject global assessment (SGA) of disease activity (range 0 to 10 in increments of 0.5), the PGA of disease activity (range 0 to 10 in increments of 0.5), and C-reactive protein (CRP) test result. Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. A SDAI score ranges from 0 (disease remission) to 86 (high disease activity).
| Score on a scale | RA- Placebo | RA- Branebrutinib |
|---|---|---|
| Change From Baseline in SDAI at Week 12- RA | -19.430 ± 12.5890 | -18.303 ± 11.5793 |
The Clinical Disease Activity Index (CDAI) is the sum of the tender joint score (range 0 to 28), the swollen joint score (range 0 to 28), the SGA of disease activity (range 0 to 10 in increments of 0.5), and the PGA of disease activity (range 0 to 10 in increments of 0.5). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment. A CDAI score ranges from 0 to 76. The interpretation of CDAI is as follows: 0.0 - 2.8: Disease remission 2.9 - 10.0: Low disease activity (LDA) 10.1 - 22.0: Moderate disease activity 22.1 - 76.0: High disease activity
| Score on a scale | RA- Placebo | RA- Branebrutinib |
|---|---|---|
| Change From Baseline in CDAI at Week 12 - RA | -19.4 ± 12.07 | -18.0 ± 11.01 |
ACR20 defined as both improvement of 20% in the number of tender and swollen joints and a 20% improvement in 3 of the following 5 criteria: * Subject global assessment (SGA) * Physician global assessment (PGA) * Functional ability measure * Pain visual analog scale (VAS) * Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.
| Percent of Participants | RA- Placebo | RA- Branebrutinib |
|---|---|---|
| Percent of Participants With ACR20 Response Compared to Baseline at Week 12 - RA | 61.9 (41.1 to 82.7) | 57.8 (45.7 to 69.9) |
ACR70 is defined as both improvement of 70% in the number of tender and swollen joints and a 70% improvement in 3 of the following 5 criteria: * Subject global assessment (SGA) * Physician global assessment (PGA) * Functional ability measure * Pain visual analog scale (VAS) * Erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP). Baseline values are defined as the last nonmissing value prior to the first dose of study treatment.
| Percent of Participants | RA- Placebo | RA- Branebrutinib |
|---|---|---|
| Percent of Participants With ACR70 Response Compared to Baseline at Week 12 - RA | 14.3 (0.0 to 29.3) | 7.8 (1.2 to 14.4) |
Collected over All-cause mortality was assessed from participants first dose to their study completion (up to approximately 32 weeks) SAEs and Other AEs were assessed from first dose to 30 days following last dose (up to approximately 30 weeks). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SLE- Placebo | 0/5 (0%) | 0/5 (0%) | 4/5 (80%) |
| SLE- Branebrutinib | 0/15 (0%) | 0/15 (0%) | 14/15 (93.3%) |
| pSS- Placebo | 0/4 (0%) | 0/4 (0%) | 4/4 (100%) |
| pSS- Branebrutinib | 0/10 (0%) | 0/10 (0%) | 8/10 (80%) |
| RA- Placebo | 0/21 (0%) | 0/21 (0%) | 6/21 (28.6%) |
| RA- Branebrutinib | 0/64 (0%) | 0/64 (0%) | 13/64 (20.3%) |
| RA Abatacept | 0/81 (0%) | 0/81 (0%) | 5/81 (6.2%) |
| Event | SLE- Placebo | SLE- Branebrutinib | pSS- Placebo | pSS- Branebrutinib | RA- Placebo | RA- Branebrutinib | RA Abatacept |
|---|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 0/5 | 2/15 | 3/4 | 2/10 | 1/21 | 1/64 | 1/81 |
| NauseaGastrointestinal disorders | 0/5 | 0/15 | 1/4 | 0/10 | 0/21 | 0/64 | 0/81 |
| DiscomfortGeneral disorders | 0/5 | 0/15 | 1/4 | 0/10 | 0/21 | 0/64 | 0/81 |
| PyrexiaGeneral disorders | 0/5 | 0/15 | 1/4 | 0/10 | 0/21 | 0/64 | 0/81 |
| SunburnInjury, poisoning and procedural complications | 0/5 | 1/15 | 1/4 | 0/10 | 0/21 | 0/64 | 0/81 |
| BursitisMusculoskeletal and connective tissue disorders | 0/5 | 0/15 | 1/4 | 0/10 | 0/21 | 0/64 | 0/81 |
| HeadacheNervous system disorders | 0/5 | 1/15 | 1/4 | 1/10 | 1/21 | 1/64 | 1/81 |
| EnterocolitisGastrointestinal disorders | 1/5 | 0/15 | 0/4 | 0/10 | 0/21 | 0/64 | 0/81 |
| GastritisGastrointestinal disorders | 1/5 | 0/15 | 0/4 | 0/10 | 0/21 | 0/64 | 0/81 |
| AstheniaGeneral disorders | 1/5 | 0/15 | 0/4 | 0/10 | 0/21 | 1/64 | 0/81 |
| Age, Continuous(Years) | SLE- Placebo | SLE- Branebrutinib | pSS- Placebo | pSS- Branebrutinib | RA- Placebo | RA- Branebrutinib | Total |
|---|---|---|---|---|---|---|---|
| Mean | 47.6 ± 10.99 | 44.2 ± 12.91 | 47.8 ± 4.19 | 46.6 ± 9.28 | 46.0 ± 12.95 | 50.1 ± 11.62 | 48.2 ± 11.68 |
| Sex: Female, Male(Participants) | SLE- Placebo | SLE- Branebrutinib | pSS- Placebo | pSS- Branebrutinib | RA- Placebo | RA- Branebrutinib | Total |
|---|---|---|---|---|---|---|---|
| Female | 5 | 14 | 4 | 7 | 18 | 45 | 93 |
| Male | 0 | 1 | 0 | 3 | 3 | 19 | 26 |
| Ethnicity (NIH/OMB)(Participants) | SLE- Placebo | SLE- Branebrutinib | pSS- Placebo | pSS- Branebrutinib | RA- Placebo | RA- Branebrutinib | Total |
|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 3 | 9 | 0 | 1 | 1 | 7 | 21 |
| Not Hispanic or Latino | 2 | 6 | 4 | 8 | 20 | 57 | 97 |
| Unknown or Not Reported | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Race/Ethnicity, Customized(Participants) | SLE- Placebo | SLE- Branebrutinib | pSS- Placebo | pSS- Branebrutinib | RA- Placebo | RA- Branebrutinib | Total |
|---|---|---|---|---|---|---|---|
| Asian - Non-Japanese — Asian - Non-Japanese | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Asian - Non-Japanese — Black or African American | 1 | 3 | 0 | 0 | 0 | 2 | 6 |
| Asian - Non-Japanese — White | 2 | 6 | 4 | 9 | 21 | 59 | 101 |
| Asian - Non-Japanese — Not Reported | 0 | 0 | 0 | 1 | 0 | 1 | 2 |
| Asian - Non-Japanese — American Indian or Alaska Native | 2 | 6 | 0 | 0 | 0 | 0 | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2020 to primary completion in Dec 2022, 34 months.
Results were first posted in Jan 2024, 1 year 1 month after primary completion.
Of 60 phase 2 interventional studies under Autoimmune Diseases, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 100. This study's 34 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Branebrutinib · Abatacept